NPO Microgen, a company of the Naimbio holding, is launching on the market the first domestic human normal immunoglobulin for intravenous administration in the form of a 10% solution. The novelty will substitute for its foreign analogues available on the market and increase the availability and quality of therapy for patients with immunodeficiency conditions.

The drug, which received the trade name BioGam, is administered intravenously as a replacement and immunomodulatory therapy in patients with reduced or absent antibody response. Injection of an immunoglobulin solution will compensate for the deficiency and increase the level of antibodies to optimal physiological values, hence reduce the risk of infections.

Similar drugs are used globally for the treatment of congenital and acquired immunodeficiencies, such as HIV infection, Guillain-Barré syndrome, Kawasaki disease, for the treatment and prevention of infectious diseases, as well as in organ transplantation.

Andrey Zagorsky

CEO, Nacimbio

Natsimbio is the first among Russian companies to market an intravenous immunoglobulin drug in a 10% concentration. Such drugs are crucial for the quality of life of patients with immunodeficiency. Their main difference is that with high concentrations, optimal results in therapy can be achieved with smaller volumes of the drug and in less time. This is especially important for pediatric practice, therapy of pregnant women, patients with cardiovascular diseases and renal pathology.